AI-generated summary
The authors report a randomized, sham-controlled trial of multiwavelength photobiomodulation in 100 people with dry age-related macular degeneration over 24 months. They report better visual acuity at month 21 in the treated group, fewer progressions to geographic atrophy at month 24, and no signs of phototoxicity.
- Participants
- 100
- Who or what was studied
- Adults with nonexudative (dry) age-related macular degeneration; 148 eyes from 100 subjects were randomized
- Wavelengths
- 590, 660, 850 nm
- Limits stated in the abstract
- The abstract does not describe the study's statistical power, the magnitude of effects beyond reported letter gains, or long-term outcomes beyond 24 months.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on ovid.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Age-related macular degeneration, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.